Literature-reported optimized formulation
Component: TTP-3 | mol%: 60.0 | Role: Ionizable lipid
sales@dcchemicals.com
TTP-3
Literature records
Search the tables and observations reproduced from the product literature guide. Rows may represent measurements, recipes or experimental context; they are not all independent experiments.
Literature-reported optimized formulation
Component: DOPE | mol%: 10.0 | Role: Helper phospholipid
Literature-reported optimized formulation
Component: β-Sitosterol | mol%: 27.5 | Role: Sterol lipid
Literature-reported optimized formulation
Component: C14-PEG2000 | mol%: 2.5 | Role: PEG lipid
Literature-reported optimized formulation
Component: Total | mol%: 100.0 | Role:
Table 2
Component: TTP-3 | Molecular weight: 816.35 | Reported molar parts: 60.0 | Calculated mass: Not calculated
Table 2
Component: DOPE | Molecular weight: 744.034 | Reported molar parts: 10.0 | Calculated mass: Not calculated
Table 2
Component: β-Sitosterol | Molecular weight: 414.71 | Reported molar parts: 27.5 | Calculated mass: Not calculated
Table 2
Component: C14-PEG2000 | Molecular weight: Not confirmed | Reported molar parts: 2.5 | Calculated mass: Not calculated
Reported observation
Fig. S14 Encapsulation · pre-nebulization 84.14 ± 2.52% sup-tRNA · mean ± SD
Reported observation
Fig. S14 Diameter · pre-nebulization 125.97 ± 13.38 nm hydrodynamic · mean ± SD
Reported observation
Fig. 3K In vivo lung reporter Superior vs A10-LIN (P = 0.0010) and MC3 (P < 0.0001)
Reported observation
Fig. 4C–E Epithelial share ~60% of tRNA_Aptamer-positive lung cells
Reported observation
Fig. 4E Epithelial uptake ~32% tRNA_Aptamer-positive · MC3 ~13%
Reported observation
Fig. 4F Airway subsets 22% · 19% · 32% ciliated · club · basal cells
Reported observation
Fig. S18 Ionocytes ~15% tRNA_Aptamer-positive
Reported observation
Fig. S14 Post-nebulization 54.97 ± 2.60% EE; size 204.40 ± 3.01 nm